Finally, targeting of IAPs resulting in upregulation by means of the NFKB pathway has been approached via the activation of the apoptosis-ligand receptors of the Apo2/TRAIL, most normal cells being resistant to treatment with TRAIL while cancer cell lines are sensitive to Apo2/TRAIL. This evidence concerns the gene TNFRSF10A and cancer.